Semax

Semax, synthetically developed, has been widely investigated for its potential mechanism of action and praised for its apparent biological stability. Researchers suggest it may inhibit select enzymes that regulate the degradation of enkephalins, naturally released and secreted neurotransmitters in the brain, which scientists believe may regulate various biological functions. Enkephalins are believed to be significantly involved in nociception (the sensory perception of pain) and the stress response. Furthermore, an elevation in enkephalin concentrations could potentially impact other neurotransmitter systems due to the intricate interconnections between the opioid system and neurotransmitters such as dopamine and serotonin. This interaction may manifest through the modulation or alteration of neurotransmitter release, receptor activity, or signal transduction pathways, indicating a sophisticated and multifaceted relationship that remains an area of active research. In addition to enkephalins, Semax has been evaluated for its potential to inhibit other peptide-degrading secreted enzymes.

Based on a specific research study,(4)Semax may induce elevated secretion and release of dopamine, as well as possibly increasing levels of brain-derived neurotrophic factor (BDNF). Based on another study,(5)it has been speculated that Semax also harbors the potential to alter gene expressions modulating the immune system. By altering gene expression, immune cell levels and their mobility may rise. Researchers reported that Semax exhibits potential for alteration in the encoding of chemokines and immunoglobulins, related to vascular system functioning.

Chemical Composition

• Molecular Formula: C39H54N10O10S
• Molecular Weight: 854.99 g/mol
• Other Known Titles: ACTH (4-7)PGP, HY-P1146

An initial study(6) was conducted on the hormone ACTH and its analogues, including Semax, to determine their nootropic potential in murine models. After peptide exposure in the models, 5-hydroxyindoleacetic acid (5-HIAA) levels were monitored. 5-HIAA levels appeared elevated by 25% after 2 hours of Semax presence. Levels appeared to increase gradually to a maximum of 180% within 4 hours after peptide exposure. Researchers noted that the peptide, when introduced 20 minutes prior to D-amphetamine, appeared to lead to an elevation of 5-HIAA compared to Semax exposure alone. 5-HIAA is a primary metabolite of serotonin, indicating that Semax might enhance serotonergic activity. This hypothetical influence on serotonin metabolism could enhance the functions of serotonin-dependent pathways, which may affect operations within the central nervous system. This speculative action underscores a possible modulation of neurotransmitter systems that play critical roles in mood, cognition, and general brain function.

The main objective of this study(7) was to expose neonatal murine models to an SSRI and then to Semax, to evaluate the interaction. Murine models between 1 and 14 days old received an SSRI, followed by Semax on days 15 to 28. After 28 days, it was observed that following SSRI exposure, rats exhibited anxiety-like behavior, with an apparently impaired response to stressors and novel stimuli during the first 14 days. After Semax exposure, these SSRI-induced actions appeared to be mitigated, with rats even exhibiting improved learning capabilities and a general reduction in anxiety-driven behaviors. Researchers posited that Semax might have re-established normal monoamine levels in the brain, which may have been initially diminished by the SSRI. By affecting these neurotransmitter systems, Semax might restore or stabilize neural pathways that were previously disrupted. Such changes could balance excitatory and inhibitory signals in the brain, creating a state more conducive to reducing anxiety. For example, by potentially increasing serotonin levels, Semax may improve mood and decrease anxiety, while optimizing dopamine could enhance motivation and reward processing. Additionally, norepinephrine adjustments could improve attention and vigilance. Behavioral assessments conducted in the experiment indicated that these potential Semax actions appeared temporally stable. The reduction in anxiety-related behaviors was maintained from adolescence into early adulthood, suggesting that Semax might have a lasting influence on neuronal circuits. This enduring stability implies that Semax might support the creation of a protective or corrective action in these circuits that persists beyond immediate exposure.

In this study,(8) researchers evaluated Semax's potential to protect murine heart models from vascular damage following experimental myocardial infarction (MI). Murine models were induced with myocardial infarction, and a cohort of the models was exposed to Semax in an experimental group for the following 6 days. On day 28, researchers reported that murine models serving as the control group appeared to have developed cardiac hypertrophy along with a decrease in blood pressure. Models exposed to Semax exhibited signs indicating prevention of diastolic pressure growth in the left ventricle, with apparent remodeling of the left ventricle. Notably, the peptide may have improved both cardiomyocyte hypertrophy and the imbalance between contractile and mitochondrial apparatus growth.

Adolescent rats(9) were separated from their mothers for approximately 5 hours per day during postnatal days 1 to 14. From days 15 to 28, these adolescent rats were exposed to the peptide Semax. After 28 days, it was found that during maternal deprivation, when Semax was not present, there was an apparent increase in anxiety and physical and emotional reactivity in the rats. Following Semax exposure, researchers reported that reactions and anxiety in the rats appeared restored to control levels.

This clinical trial(10) was conducted on 100 ischemic stroke models. A cohort representing 30% of the models was exposed to Semax, while the rest were evaluated as a control group. After the study, researchers reported that following Semax exposure, there appeared to be an improvement in the rate of restoration of damaged neurological functions. All results were analyzed using EEG mapping.

A small-scale clinical trial(11) was conducted in which Semax was administered to research models under high-stress conditions, and subsequent brain activity was monitored. At the end of the study, after a total of 24 hours, researchers reported that, compared to normal pre-trial thresholds, the models appeared to exhibit greater memory recall and increased concentration intervals.